GenTel Obtains Rights From Van Andel Research Institute to Sell Protein Array Tool | GenomeWeb
NEW YORK (GenomeWeb News) – The Van Andel Research Institute granted GenTel Biosciences exclusive rights to use its technology to commercialize a microarray platform that measures variations in protein glycosylation.
 
GenTel plans to use the technology with its PANDEIAT system to label serum proteins and probe cancer biomarker-specific antibody arrays to measure both the protein abundance and the degree of protein glycosylation, the company said.
 
Financial details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.